COPENHAGEN (Reuters) -Novo Nordisk said on Wednesday its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for patients in an early-stage trial, with mild-to-moderate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback